- Home
- ABBV
ABBV
AbbVie Inc.
as 01-17-2025 4:00pm EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 310.3B | IPO Year: | N/A |
| Target Price: | $207.25 | AVG Volume (30 days): | 5.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 22 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.87 | EPS Growth: | -21.44 |
| 52 Week Low/High: | $153.58 - $207.32 | Next Earning Date: | 01-31-2025 |
| Revenue: | $55,533,000,000 | Revenue Growth: | 0.72% |
| Revenue Growth (this year): | 5.28% | Revenue Growth (next year): | 5.79% |
Stock Insider Trading Activity of AbbVie Inc. (ABBV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Buckbee Kevin K | ABBV | SVP, CONTROLLER | Dec 16 '24 | Sell | $172.24 | 1,800 | $310,032.00 | 6,983 |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
TipRanks
2 days ago
Count on Dividend King Pepsi (PEP) for Stability in a Volatile Market
Insider Monkey
2 days ago
Why Is AbbVie Inc. (ABBV) Among Louis Navellier’s Top Long-term Stock Picks?
TipRanks
3 days ago
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
Zacks
3 days ago
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
Benzinga
3 days ago
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
Yahoo Finance
4 days ago
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
MT Newswires
4 days ago
Guggenheim Adjusts Price Target on AbbVie to $212 From $221, Maintains Buy Rating
MT Newswires
4 days ago
Redburn Atlantic Adjusts Price Target on AbbVie to $216 From $214, Maintains Buy Rating
Compare ABBV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.